CytRx concedes that its only drug flunked a PhIII sarcoma test, routing shares
Three years after one of its drugs had to be scrapped following a failed study, CytRx was forced to concede that its Phase III study of its lead drug aldoxorubicin flopped against treatment resistant soft tissue sarcomas.
The company tried to put the most positive spin on it, saying that the results had been confounded by an interruption due to a temporary partial clinical hold in 2014. But the progression-free survival rate for the drug came in at 4.17 months, hardly distinguishable from the 4.04 months tracked for investigators’ choice among standard treatments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.